HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Fibrosis (Cirrhosis)

Any pathological condition where fibrous connective tissue invades any organ, usually as a consequence of inflammation or other injury.
Also Known As:
Cirrhosis; Fibroses
Networked: 100260 relevant articles (6823 outcomes, 12245 trials/studies)

Relationship Network

Disease Context: Research Results

Related Diseases

1. Inflammation (Inflammations)
2. Fibrosis (Cirrhosis)
3. Hepatocellular Carcinoma (Hepatoma)
4. Hypertrophy
5. Liver Cirrhosis (Hepatic Cirrhosis)

Experts

1. Zhang, Wei: 159 articles (10/2022 - 04/2002)
2. Li, Jun: 148 articles (10/2022 - 07/2004)
3. Wang, Wei: 147 articles (08/2022 - 02/2003)
4. Sanyal, Arun J: 135 articles (12/2022 - 01/2003)
5. Trauner, Michael: 125 articles (12/2022 - 12/2005)
6. Trebicka, Jonel: 122 articles (05/2022 - 06/2005)
7. Zhang, Yan: 117 articles (12/2022 - 03/2002)
8. Li, Yan: 108 articles (12/2022 - 01/2005)
9. Wang, Jing: 107 articles (07/2022 - 03/2007)
10. Distler, Oliver: 107 articles (01/2022 - 10/2005)

Drugs and Biologics

Drugs and Important Biological Agents (IBA) related to Fibrosis:
1. CollagenIBA
2. Proteins (Proteins, Gene)FDA Link
3. Bleomycin (Blenoxane)FDA LinkGeneric
4. Antiviral Agents (Antivirals)IBA
5. Biomarkers (Surrogate Marker)IBA
6. CytokinesIBA
7. InterferonsIBA
8. AntioxidantsIBA
9. Ribavirin (Virazole)FDA LinkGeneric
12/01/2006 - "Thus, (1) patients with genotypes 2 and 3 and severe fibrosis can be treated with low dose of Peg-IFN and ribavirin, (2) this study suggests that patients with genotypes 1, 4 and 5 and high viraemia could receive a standard dose of Peg-IFN associated with ribavirin for 48 weeks, (3) side effects limit the efficacy of the treatment with standard dose of Peg-IFN in patients with genotypes 1, 4 and 5 and low viraemia, (4) more studies are needed for patients with genotype 2 or 3 to define the optimal duration (24 or 48 weeks) in patients with severe fibrosis."
08/01/2015 - "Ribavirin is required only for some treatment regimens and may be particularly beneficial in patients with cirrhosis. "
04/01/2000 - "Although current evidence suggests that the combination of ribavirin and IFN-alpha might be more efficacious than IFN alone in increasing the response rate in patients in the advanced fibrotic stage, the efficacy of this regimen for patients with well-compensated HCV-related cirrhosis is still unknown and prospective well-designed studies are urgently needed. "
06/27/2022 - "While the addition of ribavirin (RBV) to SOF/VEL improved sustained virological response (SVR12) in genotype 3 (GT3) decompensated cirrhosis patients, the benefits of RBV in GT3 compensated cirrhosis patients receiving SOF/VEL remains unclear. "
03/01/2005 - "A recent clinical trial of peginterferon alpha-2a plus ribavirin in African American patients resulted in a higher SVR rate, 26%, than observed previously, and 90% of patients showed stabilization or improvement in fibrosis. "
10. Glucose (Dextrose)FDA LinkGeneric

Therapies and Procedures

1. Therapeutics
2. Liver Transplantation
3. Transplantation
4. Transjugular Intrahepatic Portasystemic Shunt
5. Aftercare (After-Treatment)